Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · 600mg/300mg/200mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549
Manufacturer: Teva Canada Limited; listing date 2017-09-28
Health Canada: Marketed since 2017-07-26 · brand TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EFAVIRENZ 600 MG, EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Teva canada limited · schedule Prescription
Teva-Efavirenz/Emtricitabine/Tenofovir: Formulary list price $11.3300/unit (unit not stated in source; not the patient's cost)
Ministry pays: $11.3300 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87876 · Verify on the e-Formulary ↗ (DIN 02393549)
Source record
DIN 02393549: Teva-Efavirenz/Emtricitabine/Tenofovir
Raw flags: sec3=Y
Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id TEV
Source form: Tab; strength: 600mg/300mg/200mg
Recorded listing: General benefit
Source prices (unrounded): $11.3300; ministry $11.3300
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02393549
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87876
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300
Atripla · DIN 02300699 · $11.3300
Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300
Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300
Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300
PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300
Shortage status: not checked (no credentials)